Evaluation of alpha-fetoprotein assay in ascitic fluid for the diagnosis of hepatocellular carcinoma

Clinica Chimica Acta

Volumn 280, Issue 1-2, 1999, Pages 161-171

  Miédougé, Marcel ^a   Salama, Gilles ^a   Barange, Karl ^b   Vincent, Christian ^a   Vinel, Jean Pierre ^b   Serre, Guy ^a  

^a INSERM   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

AFP; Albumin; Alpha fetoprotein; Ascitic fluid; Hepatocellular carcinoma

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; PROTEIN;

ADULT; AGED; ANALYZER; ASCITES FLUID; ASCITES FLUID LEVEL; ASSAY; BLOOD LEVEL; CANCER DIAGNOSIS; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ALPHA-FETOPROTEINS; ASCITIC FLUID; CARCINOMA, HEPATOCELLULAR; EVALUATION STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 0344097385     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(98)00184-3     Document Type: Conference Paper

References (27)

1. Colombo M, de Franchis R, del Ninno Eet al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 325:1991;675-680.
2. Ramsey WH, Wu GY Hepatocellular carcinoma: update on diagnosis and treatment. Dig Dis. 13:1995;81-91.
3. Simonetti RG, Camma C, Fiorello F, Politi F, D'Amico G, Pagliaro L Hepatocellular carcinoma: a world-wide problem and the major risk factors. Dig Dis Sci. 36:1991;962-972.
4. Khakoo SI, Grellier LFL, Bhattcharya S, Dusheiko M Aetiology, screening and treatment of hepatocellular carcinoma. Med Clin North Am. 80:1996;1121-1145.
5. Ganne-Carrié N, Chastang C, Chapel Fet al. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis. Hepatology. 23:1996;1112-1118.
6. Taketa K Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 6:1990;1420-1432.
7. Nomura F, Ohnishi K, Tanabe Y Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Cancer. 64:1989;1700-1707.
8. Witte MH, Witte CL, Dumont AE Estimated net transcapillary water and protein flux in the liver and intestine of patients with portal hypertension from hepatic cirrhosis. Gastroenterology. 80:1981;265-272.
9. Henriksen JH Permselectivity of the liver blood-lymph (ascitic fluid) barrier to macromolecules in decompensated cirrhosis: relation to calculated pore-size. Clin Physiol. 3:1983;163-171.
10. Daste G, Serre G, Mauduyt MA, Vincent C, Caverivière P, Soleilhavoup JP Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves cytodiagnosis of serous effusions. Cytopathology. 2:1991;19-28.
11. Fiore M, Mitchell J, Doan Tet al. The Abbott IMX automated benchtop immunochemistry analyser system. Clin Chem. 34:1988;1726-1732.
12. Hanley JA, McNeil BJ A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 148:1983;839-843.
13. Dunk AA, Spiliadis H, Sherlock Set al. Hepatocellular carcinoma: clinical, aetiological and pathological features in British patients. Int J Cancer. 41:1988;17-23.
14. Runyon BA, Hoefs JC, Morgan TR Ascitic fluid analysis in malignancy related ascites. Hepatology. 8:1988;1104-1109.
15. Lee CM, Changchien CS, Shyu WC, Liaw YF Serum-ascites albumin concentration gradient and ascites fibronectin in the diagnosis of malignant ascites. Cancer. 70:1992;2057-2060.
16. Salerno F, Restelli B, Incerti Pet al. Utility of ascitic fluid analysis in patients with malignancy-related ascites. Scand J Gastroenterol. 25:1990;251-256.
17. Gillery P, Bajolet O, Rouzaud E, Le Tarnec A, Borel JP Is assay of alpha-fetoprotein in ascitic fluid of clinical interest? Clin Chem. 32:1986;1592.
18. Rosendale BE, Dusenbery D Cytology of hepatocellular carcinoma in serous fluid: a report of three cases. Diagn Cytopathol. 15:1996;127-131.
19. Falconieri G, Zanconati F, Colautti Iet al. Effusion cytology of hepatocellular carcinoma. Acta Cytol. 39:1995;893-897.
20. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, Martin-Escribano P, Ortuno-De-Solo B, Estenoz-Alfaro J Diagnostic value of CA 72-4, carcinoembryonic antigen, CA 15-3 and CA 19-9 assay in pleural fluid. Cancer. 78:1996;736-740.
21. Gerbes AL, Jungst D, Xie Y, Permanetter W, Paumgartner G Ascitic fluid analysis for the differentiation of malignancy-related ascites and non-malignant ascites. Cancer. 68:1991;1808-1814.
22. Kasahara A, Hayashi N, Fusamoto Het al. Clinical evaluation of plasma des-gamma-carboxy prothrombin as a marker protein of hepatocellular carcinoma in patients with tumors of various sizes. Dig Dis Sci. 38:1993;2170-2176.
23. Seregni E, Botti C, Bombardieri E Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. Anticancer Res. 15:1995;1491-1500.
24. Yamashita F, Tanaka M, Satomura S, Tanikawa K Prognosis significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology. 111:1996;996-1001.
25. Shiraki K, Takase K, Tameda Y, Hamada M, Kosaka Y, Nakano T A clinical study of lectin-reactive alpha-fetoprotein as early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients. Hepatology. 22:1995;802-807.
26. Aoyagi Y, Saitoh A, Suzuki Yet al. Fucosylation index of alphafetoprotein, a possible aid in the early recognition of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 17:1993;50-52.
27. Castaldo G, Intrieri M, Calcagno Get al. Ascitic pseudouridine discriminates between hepatocarcinoma-derived ascites and cirrhotic ascites. Clin Chem. 42:1996;1843-1846.